New Acne Treatment, Bellafil, Approved by The FDA and Found 84 Percent Effective

 

Acne has been the cause of a lot of anxieties, worries and misfortune to a lot of people. According to research almost 85 percent of people have acne one time or another in their life. If you are an adolescent most likely you will suffer from acne or acne scarring. About 40 percent of adolescents suffer from it.

Currently, there’s few effective treatment for acne: having it removed surgically by dermatologists, laser resurfacing, and microdermabrasion among others.

However, there’s another technique of acne scar removal that was just approved by The U.S. Food and Drug Administration called Bellafil. It is manufactured by a drug company located in San Diego, Suneva Medical Inc.

The agency said it is an injectable gel that works by increasing the mass of skin and elevating it to its immediate surroundings, smoothening the sunken acne scar.

The approval was granted after 6 months of testing. There were 87 patients treated by Bellafil and 67 percent showed improve skin conditions compared to 33 percent of patients treated by placebo.

Six months after the testing, the satisfaction rating increased to 84 percent. The reaction of the patients were either “very satisfied”, “satisfied” or “somewhat satisfied”. On the other hand, only 52% of those who were given the placebo said they were satisfied.

Likewise, after six months of treatment, doctors who had no idea which patients were treated with Bellafil testified 84 percent of them were “improved” or “much improved” compared to 54 percent of those who received a placebo.

A placebo is a substance used as control in testing drugs and has no therapeutic effect. They contain no effective ingredients. 

According to Dr. Jeffrey Salomon, an assistant clinical professor of plastic surgery at Yale University School of Medicine, Bellafil is considered a cosmetic procedure and is not therefore included in insurance coverage.

One injection costs a thousand dollars.

 

facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Leave a Reply

Your email address will not be published. Required fields are marked *